Fontolizumab
Fontolizumab (pronunciation: fon-toh-lih-zoo-mab) is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is an experimental drug that has been studied in clinical trials for conditions such as Crohn's disease and rheumatoid arthritis.
Etymology
The name "Fontolizumab" is derived from the Latin word "fontalis," meaning "of a spring," and "zumab," a common suffix for humanized monoclonal antibodies.
Mechanism of Action
Fontolizumab works by targeting and neutralizing interferon gamma, a cytokine that plays a crucial role in inflammation and immune response. By blocking the action of interferon gamma, fontolizumab can help reduce inflammation and alleviate symptoms in patients with autoimmune diseases.
Clinical Trials
Fontolizumab has been tested in several clinical trials. In a Phase II trial for Crohn's disease, the drug showed promise in reducing symptoms and improving quality of life for patients. However, further research is needed to confirm these results and determine the long-term safety and efficacy of fontolizumab.
Related Terms
- Monoclonal antibody
- Autoimmune disease
- Interferon gamma
- Inflammation
- Immune response
- Clinical trial
- Crohn's disease
- Rheumatoid arthritis
External links
- Medical encyclopedia article on Fontolizumab
- Wikipedia's article - Fontolizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski